Bhatt Harshil
Goshen Hospital, Goshen, IN, USA.
Indiana University School of Medicine, South Bend, IN, USA.
Clin Exp Gastroenterol. 2021 Feb 2;14:27-32. doi: 10.2147/CEG.S276361. eCollection 2021.
Pancreatitis is a serious complication of endoscopic retrograde cholangiopancreatography, with incidence rates as high as 16% in some centers. Recent studies have also shown an upward trend in hospitalization due to endoscopic retrograde cholangiopancreatography-related pancreatitis. Early interventions taken before, during, and after the procedure can significantly reduce the risk of pancreatitis and decrease morbidity and mortality of the patients. To select appropriate patients for endoscopic retrograde cholangiopancreatography, in-depth knowledge of the patient-related and procedure-related risk factors is required. This updated clinical review outlines various pharmacological agents and surgical methods used for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis. Current evidence supports the use of rectal non-steroidal anti-inflammatory drugs and pancreatic stent placement as an effective preventive strategy. Further research is needed to compare these preventive modalities to improve patient outcomes after endoscopic retrograde cholangiopancreatography.
胰腺炎是内镜逆行胰胆管造影术的一种严重并发症，在一些中心发病率高达16%。近期研究还显示，因内镜逆行胰胆管造影术相关胰腺炎而住院的人数呈上升趋势。在手术前、手术期间和手术后采取的早期干预措施可显著降低胰腺炎风险，并降低患者的发病率和死亡率。为了选择合适的患者进行内镜逆行胰胆管造影术，需要深入了解与患者相关和与手术相关的风险因素。这篇更新的临床综述概述了用于预防内镜逆行胰胆管造影术后胰腺炎的各种药物和手术方法。目前的证据支持使用直肠非甾体抗炎药和放置胰腺支架作为一种有效的预防策略。需要进一步研究来比较这些预防方式，以改善内镜逆行胰胆管造影术后的患者预后。
